The inaugural Circulating Cancer Biomarkers meeting is the only event of its kind to focus on the wide range of potential circulating biomarkers including CTCs, Circulating Endothelial Cells, Circulating Tumor DNA, Circulating miRNAS, Circulating Microvesicles and Circulating Oncoproteins with a clear commercial focus to turn these promising biomarkers into a clinical reality.

Goals:

Gain in depth knowledge on how to overcome regulatory hurdles and commercialization challenges: Hear from the FDA on how you can turn CCB research into a viable commercial entity

Understand how researchers at George Washington University are using miRNAs for early detection and management of breast cancer, and what this means for patient treatment regimes

Discover what are the best strategies currently being used in industry for development of CTCs as a potential clinical diagnostic tool. Hear from industry experts at Daiichi Sankyo, Pfizer, Human Genome Sciences and MedImmune

Get a master class in the use of circulating cancer biomarkers in oncology clinical trials with Medimmune and GSK so you can cut trial time and minimize phase III failure rates

Learn from Genentech how mutation profiling is being used to monitor on-treatment changes and potential resistance mechanisms allowing you to tailor treatment regimes and get maximum response.

Get an unbiased analysis of the advantages and disadvantages of the various rapidly-evolving technical platforms so you can assess where to best spend your valuable R&D budget